Welcome to our dedicated page for Alcon SEC filings (Ticker: ALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alcon Inc.'s SEC filings document its status as a foreign private issuer and the formal disclosures supporting its eye care operations. Form 6-K reports include interim financial reports, annual report materials, press-release exhibits and AGM invitations covering the Surgical and Vision Care franchises, product-launch activity, segment sales, earnings measures, cash flow, R&D, tariffs, acquisitions and integration items.
The filings also record governance and capital-structure matters, including annual shareholder votes, board and compensation committee elections, compensation approvals, dividends, share repurchase authorizations, issued capital, reserves and borrowing-facility data reported in XBRL.
Alcon filed investor materials supporting its proposed all-cash acquisition of STAAR Surgical at $28 per share, and plans outreach to STAAR stockholders. The materials emphasize offer context and comparisons, noting a 59% premium to the 90‑day VWAP of $18 and a 47% premium to the median sell-side price target of $19. Alcon also states it is the only interested buyer and encourages a board‑run 45‑day go‑shop without matching rights or a break‑up fee if a superior proposal emerges.
The communications reiterate that STAAR’s definitive proxy statement on Schedule 14A was filed and mailed on September 16, 2025, and include standard forward‑looking statements and risk factors, such as the need for stockholder approval and regulatory clearances. Alcon positions the transaction as aligned with sector precedents and at the high end of comparable ophthalmology deal multiples.
Alcon filed investor materials supporting its proposed all-cash acquisition of STAAR Surgical at $28 per share, and plans outreach to STAAR stockholders. The materials emphasize offer context and comparisons, noting a 59% premium to the 90‑day VWAP of $18 and a 47% premium to the median sell-side price target of $19. Alcon also states it is the only interested buyer and encourages a board‑run 45‑day go‑shop without matching rights or a break‑up fee if a superior proposal emerges.
The communications reiterate that STAAR’s definitive proxy statement on Schedule 14A was filed and mailed on September 16, 2025, and include standard forward‑looking statements and risk factors, such as the need for stockholder approval and regulatory clearances. Alcon positions the transaction as aligned with sector precedents and at the high end of comparable ophthalmology deal multiples.